<DOC>
	<DOCNO>NCT01855451</DOCNO>
	<brief_summary>A standard treatment patient head neck cancer radiation give high dos chemotherapy drug call cisplatin , give every 3 week radiation . This treatment effective significantly increase side effect difficulty swallowing , sore mouth , fatigue , hear loss , ring ear kidney failure . In Australia , commonly use treatment HPV-Associated Oropharyngeal Squamous Cell Carcinoma low dose cisplatin give weekly radiation . The high dose low dose schedule result similar total dose cisplatin give radiation , thought weekly schedule result few side effect maintain effectiveness . Another approach widely use around world patient head neck cancer , administer antibody , cetuximab , weekly radiation . Cetuximab different side effect profile cisplatin , report result less exacerbation radiation relate side effect . Both cetuximab cisplatin reduce growth cancer increase effectiveness radiation . Both cisplatin cetuximab appear effective treatment combination radiation , directly compare . The purpose study compare treatment related side effect ( acute long term ) cisplatin cetuximab regimen . Both treatment would give dose radiation therapy 7 week . The result trial help determine optimal treatment patient HPV-Associated Oropharyngeal Squamous Cell Carcinoma .</brief_summary>
	<brief_title>Weekly Cetuximab/RT Versus Weekly Cisplatin/RT HPV-Associated Oropharyngeal Squamous Cell Carcinoma</brief_title>
	<detailed_description>Human Papilloma Virus ( HPV ) -associated oropharyngeal squamous cell carcinoma ( OPSCC ) increase incidence improve prognosis compare head neck malignancy treat standard combination chemoradiation . The current standard regimen high dose cisplatin Radiation Therapy ( RT ) head neck cancer patient result significant toxicity limit tolerance . The excellent prognosis patient HPV-positive OPSCC raise concern overtreatment current standard care , result unnecessary acute late morbidity . Therefore , investigation chemo-sparing chemo-modified regimen RT HPV-associated OPSCC compromise efficacy warrant . A number regimens less intensive high dose cisplatin use clinical practice patient good prognosis HPV OPSCC , comparative trial perform population . The trial population restrict low risk HPV-associated OPSCC . Trial Arms : A- RT ( 70 Gy 35 fraction , 5 day week 7 week ) weekly Cetuximab ( 400 mg/m2 load dose IV prior radiation , follow weekly cetuximab 250 mg/m2 duration radiotherapy ) B- RT ( 70 Gy 35 fraction , 5 day week 7 week ) weekly Cisplatin ( 40 mg/m2 IV duration radiotherapy ) Hypothesis : In patient locally advance HPV-associated OPSCC , treat weekly cetuximab conventionally fractionate radiotherapy experience less acute symptom severity patient receive weekly cisplatin conventionally fractionate radiotherapy . Patients follow weekly treatment , 1 , 3 , 5 , 9 , 13 week post-treatment month 6 , 9 , 12 , 15 , 18 , 21 , 24 , 28 , 32 , 36 , 42 , 48 , 54 , 60 post-completion treatment . Follow-up trial cease last patient accrue minimum 2 year follow-up i.e . attend 24 month post-treatment review .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Aged 18 year old 2 . Has provide write Informed Consent participation trial 3 . Histologically confirm squamous cell carcinoma oropharynx p16 positive status confirm locally immunohistochemistry 4 . Stage III ( exclude T12N1 ) stage IV ( exclude T4 , N3 , distant metastasis ) smoke history &lt; /=10 pack year . If &gt; 10 pack year nodal disease must N0 N2a . 5 . If excisional biopsy perform , patient remain eligible study provide clinically measurable disease prior commence RT . The residual disease still meet stage criterion require trial e.g . excisional biopsy node residual T3 primary , tonsillectomy T1 primary residual &gt; N2a node . 6 . No prior treatment oropharyngeal cancer 7 . Adequate haematological , renal , hepatic function define , 1 . Absolute neutrophil count ( ANC , segs + band ) &gt; /= 1.5 x 109/L 2 . Platelet count &gt; /= 100 x 109/L 3 . Total bilirubin &lt; /= 1.5 x upper normal limit 4 . ALT &lt; /= 2.5 x upper normal limit 5 . Calculated creatinine clearance ( CockcroftGault formula ) isotopic GFR &gt; 55ml/min 8 . ECOG performance status score 01 9 . Participants capable childbearing use adequate contraception intend continue use contraception least 6 month follow completion treatment 10 . Negative pregnancy test within 72 hour prior randomisation woman childbearing potential 11 . Suitable followup least 24 month per trial protocol . 12 . Sufficient proficiency English , cognitive capacity willingness complete questionnaires 1 . History unknown primary head neck 2 . T4 , N3 distant metastases 3 . Smoking history &gt; 10 pack year N2b c nodal status 4 . Women pregnant lactating . 5 . Previous radiotherapy area treat ( exclude superficial radiotherapy cutaneous malignancy ) 6 . Previous cisplatin carboplatin chemotherapy 7 . Prior EGFR target therapy kind 8 . Primary surgery affect area ( excisional biopsy allow ) 9 . Peripheral neuropathy &gt; /= grade 2 ( CTCAE v4.0 ) 10 . Sensorineural hearing impairment &gt; = grade 2 ( CTCAE v4.0 , hearing impaired , enrolled monitoring program ) may exacerbate cisplatin ( Audiometric abnormality without correspond clinical deafness ground exclusion ) 11 . Tinnitus &gt; /= grade 2 ( CTCAE v4.0 ) 12 . History interstitial lung disease evidence interstitial lung disease preregistration CT 13 . History myocardial infarction within 12 month prior study entry , uncontrolled congestive heart failure , unstable angina , active cardiomyopathy , unstable arrhythmia , uncontrolled psychotic disorder , active serious infection , active peptic ulcer disease , immunosuppression due postorgan transplantation use immunosuppressant autoimmune disorder 14 . Patients know HIV positive 15 . Other cancer diagnose : 1. 5 year prior current diagnosis ( ) subsequent evidence disease recurrence ( ii ) clinical expectation recurrence great 10 % 2. within 5 year current diagnosis , exception successfully treat basal cell squamous cell skin carcinoma , situ melanoma , carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Human Papilloma Virus</keyword>
	<keyword>HPV</keyword>
	<keyword>Oropharyngeal</keyword>
	<keyword>Squamous Cell</keyword>
	<keyword>Carcinoma</keyword>
</DOC>